Differential distribution of immunoreactive angiotensin and angiotensin-converting enzyme in rat brain

doi:10.1016/0306-4522(82)90033-1

Neuroscience

Volume 7, Issue 7, July 1982, Pages 1759-1769

https://doi.org/10.1016/0306-4522(82)90033-1 Get rights and content

Abstract

To help resolve the controversy about the brain renin-angiotensin system, the distribution of immunoreactive angiotensin in the brains of male rats was analyzed using twelve different antibodies to angiotensin II, two of which had previously been reported to stain nerve fibers in the central nervous system. The distribution of angiotensin-converting enzyme immunoreactivity was also examined using an antibody to rabbit lung converting enzyme, and the distribution of this immunoreactivity was compared to that of immunoreactive angiotensin.

Weak angiotensin-like immunoreactivity was found in cell bodies of the hypothalamic magnocellular nuclei of colchicine-treated rats and in nerve terminals of the median eminence, neurohypophysis. central nucleus of the amygdala, bed nucleus of the stria terminalis and various other sites in the brain and spinal cord of untreated rats. Staining could be demonstrated with only three antisera. Antigenic specificity was carefully studied in these antisera. Each was similar in that staining could be blocked with angiotensins I, II or III and tetradecapeptide renin substrate, although angiotensins II and III were most potent. Because of the relatively few angiotensin II antisera which could stain brain and because they are blockable with angiotensin I and tetradecapeptide renin substrate, the precise nature of immunoreactive angiotensin remains an open question.

Intense converting enzyme-like activity was localized in endothelial cells of capillaries throughout the brain, in the subfornical organ and in the ‘brush border’ of choroidal epithelial cells in contact with cerebrospinal fluid. No activity was detected in neural tissue other than the subfornical organ and occasional weak activity in some ependymal elements elsewhere.

These findings indicate that angiotensin and converting enzyme immunoreactivities are not co-distributed and raises several questions regarding the nature of, and pathway for, formation of immunoreactive angiotensin in the brain.

References (39)

ArreguiA. et al.
Angidtensin-converting enzyme: presence of high-activity in choroid plexus of mammalian brain
Eur. J. Pharmac.
(1978)
FuxeK. et al.
Immunohistochemical evidence for the existence of angiotensin II—containing nerve terminals in the brain and spinal cord in the rat
Neuroscience Letters
(1976)
FuxeK. et al.
Renin-like immunocytochemical activity in the rat and mouse brain
Neuroscience Letters
(1980)
GorensteinC. et al.
Two distinct enkphalinases: solubilization, partial purification and separation from angiotensin converting enzyme
Life Sci.
(1979)
HiroseS. et al.
Renin and proreinin in hog brain: ubiquitous distribution and high concentration in the pituitary and pineal
Brain Res.
(1980)
HorvathJ.S. et al.
Endogenous angiotensin in brain
Prog. Brain Res.
(1977)
IgicR.P. et al.
Angiotensin-converting enzyme activity in the choroid plexus and in the retina
LeeC.M. et al.
Substance P. degradation by rat brain peptidases: inhibition by SQ 20881
Biochem. Pharmac.
(1979)
PhillipsM.J. et al.
An angiotensin-like peptide in the brain
Life Sci.
(1980)
Polsky-CynkinR. et al.
Immunochemical comparison of angiotensin I-converting enzyme from different rat organs
Int. J. Biochem.
(1979)

RamsayD.S.

The brain renin-angiotensions system: a re-evaluation

Neuroscience

(1979)

RixE. et al.

Converting enzyme in the choroid plexus, brain, and kidney: immunocytochemical studies in rats

Neuroscience Letters

(1981)

VandesandeF.

A critical review of immunocytochemical methods for light microscopy

J. Neurosci. Meth.

(1979)

Van HoutenM. et al.

Radioantographic localization of specific sites for blood-borne angiotensin II in the rat brain

Brain Res.

(1980)

ZimmermanE.A. et al.

Exploration peptidexic pathways in brain by immunocytochemistry: a ten year perspective

Peptides

(1980)

BrownfieldM.S.

Distribution of neurophysin, oxytoin and vasopressin in the rat

Ph.D. Thesis Dissertation Abstracts

(1979)

CaldwellP.B. et al.

Angiotensin-converting enzyme: vascular endothelial localization

Science, N.Y.

(1976)

ChangarisD.C. et al.

Angiotensin II immunohistochemistry of the rat brain

Neuroendocrinology

(1978)

DasM. et al.

Pulmonary angiotensin-converting enzyme antienzyme antibody

Biochemistry

(1976)

Cited by (159)

Beneficial effects of Angiotensin II receptor blockers in brain disorders
2017, Pharmacological Research
A canonical brain Renin-Angiotensin System (RAS), like the canonical peripheral RAS, has long been proposed as a major regulator of brain function. Because of methodological limitations, however, this system is in urgent need of critical revision. The Angiotensin II AT1 receptors have been confirmed as key factors in the regulation of brain function, and AT1 receptor over activity has been established as a major and early injury factor in the development of many brain diseases.
Consequently, Angiotensin Receptor Blockers (ARBs), compounds widely used to treat cardiovascular and metabolic disorders, are excellent candidates for repurposing for the treatment of brain disorders.
This review will discuss some of the reasons why revisiting brain RAS is a pressing necessity, will present evidence for a participation of AT1 receptor over activity in the development of major brain disorders, and will present definite evidence of ARBs neuroprotective effects.
The review will focus on the beneficial effects of ARB therapy in stroke, neurodegenerative disorders including Alzheimer’s and Parkinson’s diseases, traumatic brain injury, radiation- induced brain damage, stress and mood disorders.
Anxiogenic-like effects induced by hemopressin in rats
2015, Pharmacology Biochemistry and Behavior
Citation Excerpt :
In comparative analyses, using bradykinin as a standard substrate for these three enzymes, which was then considered 100% of relative ratio of hydrolysis in a given period of time at maximal enzymatic velocity, it was shown that HP is hydrolyzed 152.24% by EP24.16, 140% by EP24.15 and 1146.19% by ACE (Rioli et al., 2003). The presence of these peptidases in peripheral and brain tissue is well documented (Cicilini et al., 1977; Chevillard and Saavedra, 1982; Brownfield et al., 1982; Massarelli et al., 1999; Fontenele-Neto et al., 2001), suggesting that HP could be efficiently degraded following i.p. or I.C.V. administration. HP can be hydrolyzed by EP24.15 and/or EP24.16 in different peptide bonds to generate the N-terminal fragments PVNF, PVNFK and/or PVNFKF (Rioli et al., 2003).
Hemopressin (PVNFKFLSH; HP) is an orally active peptide derived from rat hemoglobin α-chain that could act as an inverse agonist at cannabinoid type 1 receptors (CB₁). Here, we aim to investigate possible behavioral effects of HP in male Wistar rats tested in the elevated plus maze (EPM), following HP intraperitoneal (i.p., 0.05 mg/kg), oral (P.O., 0.05 and 0.5 mg/kg) or intracerebroventricular (I.C.V., 3 and 10 nmol) administration. HP induced a decrease in EPM open arm exploration, indicating an anxiogenic-like effect. However, i.p. administration of HP (1 mg/kg) followed by mass spectrometry analysis of brain-peptide extracts suggested that the intact HP does not cross the blood brain barrier. I.C.V. administrated HP produced anxiogenic-like effects that were prevented by Transient Receptor Potential Vanilloid Type 1 (TRPV₁) antagonists, 6-iodonordihydrocapsaicin (1 nmol) or SB366791 (1 nmol), but not by the CB₁ receptor antagonist AM251 (0.1 and 1 nmol). Altogether, these data suggest that I.C.V. administrated HP induces anxiogenic-like effects by activating TRPV₁ receptors. The similar anxiogenic effects observed after i.p. or P.O. administration could be due to HP fragment(s) crossing the blood brain barrier. The present results advance our knowledge about HP pharmacology and suggest concerns in future clinical studies.
Angiotensin II and CRF receptors in the central nucleus of the amygdala mediate hemodynamic response variability to cocaine in conscious rats
2010, Brain Research
Citation Excerpt :
Ang receptors in the CNS play an important role in autonomic and neurohumoral responses to behavioral and pharmacological stress (Jezova et al., 1998; Knuepfer et al., 2005; Rowe et al., 2006; Saiki et al., 1997). Ang and AT1 receptors exist in the amygdala and, in particular, in the CeA (Brownfield et al., 1982; von Bohlen und Halbach and Albrecht, 1998). Microinjection of Ang in the amygdala of the rat increases the discharge rate of amygdalar neurons and the increase can be blocked by either AT1 or AT2 receptor antagonists (Albrecht et al., 2000).
Stress or cocaine evokes either a large increase in systemic vascular resistance (SVR) or a smaller increase in SVR accompanied by an increase in cardiac output (designated vascular and mixed responders, respectively) in Sprague–Dawley rats. We hypothesized that the central nucleus of the amygdala (CeA) mediates this variability. Conscious, freely-moving rats, instrumented for measurement of arterial pressure and cardiac output and for drug delivery into the CeA, were given cocaine (5 mg/kg, iv, 4–6 times) and characterized as vascular (n = 15) or mixed responders (n = 10). Subsequently, we administered cocaine after bilateral microinjections (100 nl) of saline or selective agents in the CeA. Muscimol (80 pmol), a GABA_A agonist, or losartan (43.4 pmol), an AT₁ receptor antagonist, attenuated the cocaine-induced increase in SVR in vascular responders, selectively, such that vascular responders were no longer different from mixed responders. The corticotropin releasing factor (CRF) antagonist, α-helical CRF_9–41 (15.7 pmol), abolished the difference between cardiac output and SVR in mixed and vascular responders. We conclude that greater increases in SVR observed in vascular responders are dependent on AT₁ receptor activation and, to a lesser extent on CRF receptors. Therefore, AT₁ and CRF receptors in the CeA contribute to hemodynamic response variability to intravenous cocaine.
The Role of Functional Postsynaptic NMDA Receptors in the Central Nucleus of the Amygdala in Opioid Dependence
2010, Vitamins and Hormones
Activation of ionotropic N-methyl-d-aspartate (NMDA)-type glutamate receptors in limbic system nuclei, such as the central nucleus of the amygdala (CeA), plays an essential role in autonomic, behavioral, and affective processes that are profoundly impacted by exposure to opioids. However, the heterogeneous ultrastructural distribution of the NMDA receptor, its complex pharmacology, and the paucity of genetic models have hampered the development of linkages between functional amygdala NMDA receptors and opioid dependence. To overcome these shortcomings, high-resolution imaging and molecular pharmacology were used to (1) Identify the ultrastructural localization of the essential NMDA-NR1 receptor (NR1) subunit and its relationship to the mu-opioid receptor (µOR), the major cellular target of abused opioids like morphine, in the CeA and (2) Determine the effect of CeA NR1 deletion on the physical, and particularly, psychological aspects of opioid dependence. Combined immunogold and immuoperoxidase electron microscopic analysis showed that NR1 was prominently expressed in postsynaptic (i.e., somata, dendrites) locations of CeA neurons, where they were also frequently colocalized with the µOR. A spatial–temporal deletion of NR1 in postsynaptic sites of CeA neurons was produced by local microinjection of a neurotropic recombinant adeno-associated virus (rAAV), expressing the green fluorescent protein (GFP) reporter and Cre recombinase (rAAV–GFP–Cre), in adult “floxed” NR1 (fNR1) mice. Mice with deletion of NR1 in the CeA showed no obvious impairments in sensory, motor, or nociceptive function. In addition, when administered chronic morphine, these mice also displayed an acute physical withdrawal syndrome precipitated by naloxone. However, opioid-dependent CeA NR1 knockout mice failed to exhibit a conditioned place aversion induced by naloxone-precipitated withdrawal. These results indicate that postsynaptic NMDA receptor activity in central amygdala neurons is required for the expression of a learned affective behavior associated with opioid withdrawal. The neurogenetic dissociation of physical and psychological properties of opioid dependence demonstrates the value of combined ultrastructural analysis and molecular pharmacology in clarifying the neurobiological mechanisms subserving opioid-mediated plasticity.
Human brain contains a novel non-AT1, non-AT2 binding site for active angiotensin peptides
2008, Life Sciences
To determine whether the novel non-AT1, non-AT2 binding site for angiotensins recently discovered in rodent brains occurs in the human brain.
Radioligand binding assays of ¹²⁵I-sarcosine¹, isoleucine⁸ angiotensin II binding were carried out in homogenates of the rostral pole of the temporal cortex of human brains containing 0.3 mM parachloromercuribenzoate (PCMB), 10 µM losartan to saturate AT1 receptors, 10 µM PD123319 to saturate AT2 receptors, with or without 10 µM angiotensin II to define specific binding. Competition binding assays employed a variety of angiotensin peptides, specific angiotensin receptor antagonists, several neuropeptides and an endopeptidase inhibitor to determine pharmacological specificity for this binding site.
The novel non-AT1, non-AT2 binding site was present in similar amounts in female and male brains: Bmax 1.77 ± 0.16 and 1.52 ± 0.17 fmol/mg initial wet weight in female and male brains, respectively. The K_D values, 1.79 ± 0.09 nM for females, and 1.53 ± 0.06 nM for males were also similar. The binding site shows pharmacological specificity similar to that in rodent brains: sarcosine¹, isoleucine⁸ angiotensin II > angiotensin III > angiotensin II > angiotensin I ’ angiotensin IV > angiotensin 1–7. Shorter angiotensin fragments and non-angiotensin peptides showed low affinity for this binding site.
The presence in human brain of this novel non-AT1, non-AT2 binding site supports the concept that this binding site is an important component of the brain angiotensin system. The functional significance of this binding site, either as a novel angiotensin receptor or a highly specific angiotensinase remains to be determined.
Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons
2007, Neurobiology of Aging
Citation Excerpt :
Furthermore, ACE occurs in neurons, and high concentrations of ACE have been observed in the striatum and substantia nigra of mammals including rats [14] and humans [13]. Immunohistochemical location of AII, as well as of AII-ir terminals, has been reported in the human and rat striatum [8,52]. AT1 receptors occur in DA neurons, both in cell bodies in the substantia nigra and their terminal fields in the striatum of different mammals, including rats and humans, as revealed by autoradiography [1,2,15,58] and subsequently confirmed by immunohistochemistry [4,54] and in situ hybridization histochemistry [38].
Angiotensin II activates (via type 1 receptors) NAD(P)H-dependent oxidases, which are a major source of superoxide, and is relevant in the pathogenesis of several cardiovascular diseases and certain degenerative changes associated with ageing. Given that there is a brain renin–angiotensin system and that oxidative stress is a key contributor to Parkinson's disease, we investigated the effects of angiotensin II and angiotensin type 1 (AT₁) receptor antagonists in the 6-hydroxydopamine model of Parkinson's disease. Rats subjected to intraventricular injection of 6-hydroxydopamine showed bilateral reduction in the number of dopaminergic neurons and terminals. Injection of angiotensin alone did not induce any significant effect. However, angiotensin increased the toxic effect of 6-hydroxydopamine. Rats treated with the AT₁ receptor antagonist ZD 7155 and then 6-hydroxydopamine (with or without exogenous administration of angiotensin) showed a significant reduction in 6-hydroxydopamine-induced oxidative stress (lipid peroxidation and protein oxidation) and dopaminergic degeneration. Dopaminergic degeneration was also reduced by the NAD(P)H inhibitor apocynin. Angiotensin may play a pivotal role, via AT₁ receptors, in increasing the oxidative damage of dopaminergic cells, and treatment with AT₁ antagonists may reduce the progression of Parkinson's disease.

View all citing articles on Scopus

^*: Current address: Dr. M.S. Brownfield, Department of Anatomical and Physiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53715, U.S.A.

View full text

Differential distribution of immunoreactive angiotensin and angiotensin-converting enzyme in rat brain

Abstract

Eur. J. Pharmac.

Neuroscience Letters

Neuroscience Letters

Life Sci.

Brain Res.

Prog. Brain Res.

Biochem. Pharmac.

Life Sci.

Int. J. Biochem.

Neuroscience

Neuroscience Letters

J. Neurosci. Meth.

Brain Res.

Peptides

Distribution of neurophysin, oxytoin and vasopressin in the rat

Ph.D. Thesis Dissertation Abstracts

Angiotensin-converting enzyme: vascular endothelial localization

Science, N.Y.

Angiotensin II immunohistochemistry of the rat brain

Neuroendocrinology

Pulmonary angiotensin-converting enzyme antienzyme antibody

Biochemistry